Enveric Biosciences (NASDAQ: ENVB) — Perfil da empresa, notícias e dados financeiros
Enveric Biosciences develops innovative therapies for cancer patients, focusing on cannabinoid applications and supportive care.
Enveric Biosciences
Enveric Biosciences (NASDAQ:ENVB) is a biotech firm dedicated to developing innovative solutions designed to improve patient lives, focusing primarily on those suffering from cancer. Operating in the life sciences sector, Enveric is engaged in cutting-edge research and development activities, aimed at creating a portfolio of novel therapeutic candidates. Their projects span from the development of supportive care therapies to advancing the potential uses of cannabinoids in medical treatments, highlighting their commitment to exploring new frontiers in medicine. The objective of Enveric is to address unmet medical needs through the power of modern bioscience, ensuring better health outcomes for patients worldwide.
Resumo
Operações
Produtos e/ou serviços de Enveric Biosciences
- Developing clinically validated, cannabinoid-based pharmaceuticals for dermatological and oncological applications.
- Advancing a pipeline of synthetic cannabinoids aimed at addressing unmet medical needs in cancer care.
- Creating a platform for the discovery and development of novel psychotropic therapies for mental health.
- Leveraging proprietary AI technology for the accelerated identification and optimization of drug candidates.
- Offering supportive care products for cancer patients suffering from the side effects of chemotherapy and radiation.
- Engaging in research collaborations to explore new therapeutic areas and expand its cannabinoid-derived pharmaceutical portfolio.
equipe executiva do Enveric Biosciences
- Joseph Edward TuckerCEO & Director
- Kevin M. CoveneyChief Financial Officer
- Peter J. FacchiniChief Innovation Officer
Principais indicadores financeiros
Resultados divulgados pela Enveric Biosciences, em USD.
- Cap. de mercado
- 6,6 mi
- Receita (TTM)
- 35,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -13.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -8,8 mi | -12,1 mi | |
| 0 | -9,6 mi | -9,6 mi | |
| 0 | -16,4 mi | -17,3 mil | |
| 0 | -20 mi | -18,5 mi |